Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 3 of 3 entries
Sorted by: Best Match Show Resources per page
MEK inhibition with trametinib is a successful therapy in ganglioglioma.

Clinical case reports and reviews

Daniel EB, Ney DE, Levy JMM.
PMID: 32999736
Clin Case Rep Rev. 2020 Jun;6(2). Epub 2020 May 08.

Gangliogliomas are predominantly low-grade primary brain tumors comprised of neuronal and glial components that are found in both pediatric and young adult populations. In the majority of cases, surgical resection of these tumors is curative. However, tumor location in...

Cite
Daniel EB, Ney DE, Levy JMM. MEK inhibition with trametinib is a successful therapy in ganglioglioma. Clin Case Rep Rev. 2020;6(2)
Daniel, E. B., Ney, D. E., & Levy, J. M. M. (2020). MEK inhibition with trametinib is a successful therapy in ganglioglioma. Clinical case reports and reviews, 6(2), .
Daniel, Eliza Baird, et al. "MEK inhibition with trametinib is a successful therapy in ganglioglioma." Clinical case reports and reviews vol. 6,2 (2020).
Daniel EB, Ney DE, Levy JMM. MEK inhibition with trametinib is a successful therapy in ganglioglioma. Clin Case Rep Rev. 2020 Jun;6(2). Epub 2020 May 08. PMID: 32999736; PMCID: PMC7523693.
Copy Download .nbib Format: NLM
Clinical and molecular characterization of a multi-institutional cohort of pediatric spinal cord low-grade gliomas.

Neuro-oncology advances

Grob ST, Nobre L, Campbell KR, Davies KD, Ryall S, Aisner DL, Hoffman L, Zahedi S, Morin A, Crespo M, Nellan A, Green AL, Foreman N, Vibhakar R, Hankinson TC, Handler MH, Hawkins C, Tabori U, Kleinschmidt-DeMasters BK, Mulcahy Levy JM.
PMID: 33063010
Neurooncol Adv. 2020 Aug 24;2(1):vdaa103. doi: 10.1093/noajnl/vdaa103. eCollection 2020.

No abstract available.

Cite
Grob ST, Nobre L, Campbell KR, et al. Clinical and molecular characterization of a multi-institutional cohort of pediatric spinal cord low-grade gliomas. Neurooncol Adv. 2020;2(1):vdaa103doi: 10.1093/noajnl/vdaa103.
Grob, S. T., Nobre, L., Campbell, K. R., Davies, K. D., Ryall, S., Aisner, D. L., Hoffman, L., Zahedi, S., Morin, A., Crespo, M., Nellan, A., Green, A. L., Foreman, N., Vibhakar, R., Hankinson, T. C., Handler, M. H., Hawkins, C., Tabori, U., Kleinschmidt-DeMasters, B. K., & Mulcahy Levy, J. M. (2020). Clinical and molecular characterization of a multi-institutional cohort of pediatric spinal cord low-grade gliomas. Neuro-oncology advances, 2(1), vdaa103. https://doi.org/10.1093/noajnl/vdaa103
Grob, Sydney T, et al. "Clinical and molecular characterization of a multi-institutional cohort of pediatric spinal cord low-grade gliomas." Neuro-oncology advances vol. 2,1 (2020): vdaa103. doi: https://doi.org/10.1093/noajnl/vdaa103
Grob ST, Nobre L, Campbell KR, Davies KD, Ryall S, Aisner DL, Hoffman L, Zahedi S, Morin A, Crespo M, Nellan A, Green AL, Foreman N, Vibhakar R, Hankinson TC, Handler MH, Hawkins C, Tabori U, Kleinschmidt-DeMasters BK, Mulcahy Levy JM. Clinical and molecular characterization of a multi-institutional cohort of pediatric spinal cord low-grade gliomas. Neurooncol Adv. 2020 Aug 24;2(1):vdaa103. doi: 10.1093/noajnl/vdaa103. eCollection 2020. PMID: 33063010; PMCID: PMC7542983.
Copy Download .nbib Format: NLM
Autophagy: When to strike?.

Journal of cancer immunology

Zahedi S, Mulcahy Levy JM.
PMID: 32457939
J Cancer Immunol (Wilmington). 2020;2(1):13-16. doi: 10.33696/cancerimmunol.2.008.

No abstract available.

Cite
Zahedi S, Mulcahy Levy JM. Autophagy: When to strike?. J Cancer Immunol (Wilmington). 2020;2(1):13-16doi: 10.33696/cancerimmunol.2.008.
Zahedi, S., & Mulcahy Levy, J. M. (2020). Autophagy: When to strike?. Journal of cancer immunology, 2(1), 13-16. https://doi.org/10.33696/cancerimmunol.2.008
Zahedi, Shadi, and Mulcahy Levy, Jean M. "Autophagy: When to strike?." Journal of cancer immunology vol. 2,1 (2020): 13-16. doi: https://doi.org/10.33696/cancerimmunol.2.008
Zahedi S, Mulcahy Levy JM. Autophagy: When to strike?. J Cancer Immunol (Wilmington). 2020;2(1):13-16. doi: 10.33696/cancerimmunol.2.008. PMID: 32457939; PMCID: PMC7250464.
Copy Download .nbib Format: NLM
Showing 1 to 3 of 3 entries